Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 3/2016

01-08-2016 | Review Article

Hepatitis viruses exploitation of host DNA methyltransferases functions

Authors: Valerio Pazienza, Concetta Panebianco, Angelo Andriulli

Published in: Clinical and Experimental Medicine | Issue 3/2016

Login to get access

Abstract

Hepatitis B virus (HBV), hepatitis C virus (HCV) and Delta (HDV) infections are a global health burden. With different routes of infection and biology, HBV, HCV and HDV are capable to induce liver cirrhosis and cancer by impinging on epigenetic mechanisms altering host cell’s pathways. In the present manuscript, we reviewed the published studies taking into account the relationship between the hepatitis viruses and the DNA methyltransferases proteins.
Literature
1.
Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis–United States, 2006. MMWR Surveill Summ. 2008;57(2):1–24.PubMed
2.
Larrubia JR, et al. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J Viral Hepat. 2012;20(2):85–94.PubMedCrossRef
3.
Thomas MB, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28(25):3994–4005.PubMedPubMedCentralCrossRef
4.
Jemal A, et al. Trends in the leading causes of death in the United States, 1970–2002. JAMA. 2005;294(10):1255–9.PubMedCrossRef
5.
Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol. 2003;38(Suppl 1):S136–49.PubMedCrossRef
6.
Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271–85.PubMedCrossRef
7.
8.
9.
Kew MC, et al. Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? Br Med J (Clin Res Ed). 1984;288(6432):1727.CrossRef
10.
Romeo R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–38.PubMedCrossRef
11.
Verme G, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci. 1991;36(8):1134–6.PubMedCrossRef
12.
13.
14.
Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene. 2000;19(3):468–71.PubMedCrossRef
15.
Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834–47.PubMedCrossRef
16.
Li C, et al. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol. 2012;87(4):2193–205.PubMedCrossRef
17.
Liu H, et al. Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein. Cancer Sci. 2012;103(12):2072–81.PubMedCrossRef
18.
Ripoli M, et al. Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein. Virus Res. 2011;160(1–2):74–81.PubMedCrossRef
19.
Tan A, et al. Viral hepatocarcinogenesis: from infection to cancer. Liver Int. 2008;28(2):175–88.PubMedCrossRef
20.
Buhler S, Bartenschlager R. Promotion of hepatocellular carcinoma by hepatitis C virus. Dig Dis. 2012;30(5):445–52.PubMedCrossRef
21.
Li HP, Leu YW, Chang YS. Epigenetic changes in virus-associated human cancers. Cell Res. 2005;15(4):262–71.PubMedCrossRef
22.
Stein RA. Epigenetics–the link between infectious diseases and cancer. JAMA. 2011;305(14):1484–5.PubMedCrossRef
23.
Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–68.PubMedCrossRef
24.
25.
Irizarry RA, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41(2):178–86.PubMedPubMedCentralCrossRef
26.
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92.PubMedCrossRef
27.
Kulis M, et al. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta. 2013;1829(11):1161–74.PubMedCrossRef
28.
29.
Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997;13(8):335–40.PubMedCrossRef
30.
31.
Chan AO, Rashid A. CpG island methylation in precursors of gastrointestinal malignancies. Curr Mol Med. 2006;6(4):401–8.PubMedCrossRef
32.
Smith SS, et al. Mechanism of human methyl-directed DNA methyltransferase and the fidelity of cytosine methylation. Proc Natl Acad Sci USA. 1992;89(10):4744–8.PubMedPubMedCentralCrossRef
33.
34.
Rhee I, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416(6880):552–6.PubMedCrossRef
35.
Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci USA. 2002;99(26):16916–21.PubMedPubMedCentralCrossRef
36.
Suetake I, et al. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J Biol Chem. 2004;279(26):27816–23.PubMedCrossRef
37.
Bourc’his D, et al. Dnmt3L and the establishment of maternal genomic imprints. Science. 2001;294(5551):2536–9.PubMedCrossRef
38.
Hata K, et al. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development. 2002;129(8):1983–93.PubMed
39.
Neri F, et al. Dnmt3L antagonizes DNA methylation at bivalent promoters and favors DNA methylation at gene bodies in ESCs. Cell. 2013;155(1):121–34.PubMedCrossRef
40.
Ezzikouri S, et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol. 2009;9(5):877–81.PubMedCrossRef
41.
O’Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 2008;4(8):e1000155.PubMedPubMedCentralCrossRef
42.
43.
Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007;127(2):164–76.PubMedCrossRef
44.
45.
46.
Thomas HC, Carman WF. The host immune response may be responsible for selection of envelope and precore/core variants of HBV. Prog Liver Dis. 1992;10:239–51.PubMed
47.
Guo Y, et al. Hepatitis B viral core protein disrupts human host gene expression by binding to promoter regions. BMC Genom. 2012;13:563.CrossRef
48.
Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol. 1992;36(2):101–17.PubMedCrossRef
49.
Madden CR, Slagle BL. Stimulation of cellular proliferation by hepatitis B virus X protein. Dis Markers. 2001;17(3):153–7.PubMedCrossRef
50.
Su PF, et al. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer. 2007;121(6):1257–64.PubMedCrossRef
51.
Zhong S, et al. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res. 2002;8(4):1087–92.PubMed
52.
53.
54.
Lambert MP, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54(4):705–15.PubMedCrossRef
55.
Um TH, et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol. 2010;54(5):939–47.PubMedCrossRef
56.
Feng Q, et al. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol. 2010;88(2):287–92.PubMedPubMedCentralCrossRef
57.
Jung JK, et al. Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res. 2007;67(12):5771–8.PubMedCrossRef
58.
Park IY, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 2007;132(4):1476–94.PubMedCrossRef
59.
Kim YJ, et al. Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. Cancer Lett. 2010;288(2):226–35.PubMedCrossRef
60.
Lee SM, et al. HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators. Proc Natl Acad Sci USA. 2014;111(26):9555–60.PubMedPubMedCentralCrossRef
61.
Fan H, et al. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene. 2015. doi:10.​1038/​onc.​2015.​122
62.
Pazienza V, et al. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-γ in Huh-7 cells. J Gen Virol. 2010;91(Pt 7):1678–86.PubMedCrossRef
63.
Liu R, et al. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother. 2007;59(1):51–8.PubMedCrossRef
64.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.PubMedCrossRef
65.
Simmonds P, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993;74(Pt 11):2391–9.PubMedCrossRef
66.
Abid K, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol. 2005;42(5):744–51.PubMedCrossRef
67.
Barba G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA. 1997;94(4):1200–5.PubMedPubMedCentralCrossRef
68.
Moriya K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4(9):1065–7.PubMedCrossRef
69.
Pazienza V, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45(5):1164–71.PubMedCrossRef
70.
Nishise Y, et al. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b. J Infect Dis. 2007;196(7):1006–9.PubMedCrossRef
71.
Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther. 2011;9(9):747–59.PubMedCrossRef
72.
Ishido S, Hotta H. Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor. FEBS Lett. 1998;438(3):258–62.PubMedCrossRef
73.
Basu A, et al. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology. 2006;349(2):347–58.PubMedCrossRef
74.
Ray RB, et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res. 1995;37(3):209–20.PubMedCrossRef
75.
Hayashi J, et al. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology. 2000;32(5):958–61.PubMedCrossRef
76.
Formeister EJ, et al. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res. 2010;692(1–2):26–33.PubMedPubMedCentralCrossRef
77.
Arora P, et al. Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett. 2008;261(2):244–52.PubMedCrossRef
78.
Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5(5):806–11.PubMedCrossRef
79.
Benegiamo G, et al. DNA methyltransferases 1 and 3b expression in Huh-7 cells expressing HCV core protein of different genotypes. Dig Dis Sci. 2012;57(6):1598–603.PubMedCrossRef
80.
Chen C, et al. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. Virology. 2013;441(1):57–65.PubMedCrossRef
81.
82.
Elena SF, et al. Phylogeny of viroids, viroidlike satellite RNAs, and the viroidlike domain of hepatitis delta virus RNA. Proc Natl Acad Sci USA. 1991;88(13):5631–4.PubMedPubMedCentralCrossRef
83.
Sureau C. The role of the HBV envelope proteins in the HDV replication cycle. Curr Top Microbiol Immunol. 2006;307:113–31.PubMed
84.
Weiner AJ, et al. A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol. 1988;62(2):594–9.PubMedPubMedCentral
85.
Niro GA, Gioffreda D, Fontana R. Hepatitis delta virus infection: open issues. Dig Liver Dis. 2011;43(Suppl 1):S19–24.PubMedCrossRef
86.
Li YJ, Stallcup MR, Lai MM. Hepatitis delta virus antigen is methylated at arginine residues, and methylation regulates subcellular localization and RNA replication. J Virol. 2004;78(23):13325–34.PubMedPubMedCentralCrossRef
87.
Benegiamo G, et al. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett. 2013;587(9):1424–8.PubMedCrossRef
88.
Martin M, Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012;4(1):8.PubMedPubMedCentralCrossRef
89.
Bae SI, et al. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene. 2008;27(4):490–8.PubMedCrossRef
90.
Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010;51(3):881–90.PubMedPubMedCentral
91.
McGough JM, et al. DNA methylation represses IFN-γ-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Mol Cancer Res. 2008;6(12):1841–51.PubMedPubMedCentral
92.
Meng F, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008;27(3):378–86.PubMedCrossRef
93.
Reu FJ, et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 2006;66(5):2785–93.PubMedPubMedCentralCrossRef
94.
You H, Ding W, Rountree CB. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology. 2010;51(5):1635–44.PubMedPubMedCentralCrossRef
95.
Scheller J, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88.PubMedCrossRef
96.
Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol. 2014;44(4):1032–40.PubMed
97.
Johnson C, et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58–70.PubMedPubMedCentral
98.
Hodge DR, et al. IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. Cancer Genomics Proteomics. 2007;4(6):387–98.PubMed
99.
Wrana JL, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71(6):1003–14.PubMedCrossRef
100.
Panebianco C, Saracino C, Pazienza V. Epithelial-mesenchymal transition: molecular pathways of hepatitis viruses-induced hepatocellular carcinoma progression. Tumour Biol. 2014;35(8):7307–15.PubMedCrossRef
101.
102.
Matsumura N, et al. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res. 2011;21(1):74–82.PubMedPubMedCentralCrossRef
103.
Zhang Q, et al. TGF-beta regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS One. 2011;6(9):e25168.PubMedPubMedCentralCrossRef
104.
105.
Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21.PubMedCrossRef
106.
Pugnale P, et al. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology. 2009;49(2):398–406.PubMedCrossRef
107.
Chun JY, et al. Putative association of DNA methyltransferase 1 (DNMT1) polymorphisms with clearance of HBV infection. BMB Rep. 2009;42(12):834–9.PubMedCrossRef
108.
Shervington A, Patel R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides. 2008;18(4):365–74.PubMedCrossRef
109.
Suzuki M, et al. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res. 2004;64(9):3137–43.PubMedCrossRef
110.
Yamanaka K, et al. Gene silencing of DNA methyltransferases by RNA interference in bovine fibroblast cells. J Reprod Dev. 2010;56(1):60–7.PubMedCrossRef
111.
Brueckner B, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65(14):6305–11.PubMedCrossRef
112.
Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483–95.PubMedCrossRef
113.
114.
Schirrmacher E, et al. Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. Bioconjug Chem. 2006;17(2):261–6.PubMedCrossRef
115.
Segura-Pacheco B, et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med. 2006;4:32.PubMedPubMedCentralCrossRef
116.
Liu X, et al. Hepatitis B virus DNA-induced carcinogenesis of human normal liver cells by virtue of non-methylated CpG DNA. Oncol Rep. 2009;21(4):941–7.PubMed
Metadata
Title
Hepatitis viruses exploitation of host DNA methyltransferases functions
Authors
Valerio Pazienza
Concetta Panebianco
Angelo Andriulli
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 3/2016
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0372-3

Other articles of this Issue 3/2016

Clinical and Experimental Medicine 3/2016 Go to the issue

Original Article

The tumor necrosis factor-α-238 polymorphism and digestive system cancer risk: a meta-analysis

Review Article

The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review

Original Article

Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma

Review Article

T cell senescence and cardiovascular diseases

Original Article

miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor

Original Article

Leukocytes apoptosis and adipocytokines in children with beta thalassemia major

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits